Keyword: Japan

Tokyo-based Heartseed has raised 2.8 billion yen, or about $26 million U.S., to help develop its stem cell-based treatment for heart failure.

The agreement will give Bayer the chance to explore drug targets based on research at a leading Japanese scientific research institute.

The submission moves Gilead a step closer to selling the Galapagos-partnered drug to rheumatoid arthritis patients in the country. 

Tokyo-based AI Medical Service has raised about $43 million to fund its artificial intelligence programs that analyze endoscopy images.

As Celgene gradually phases into parent company Bristol-Myers Squibb, this is leaving little room at the inn for some of the top execs.

The filing follows data from Japanese phase 3 trials that assessed the oral HIF-PHI in chronic kidney disease patients.

The biotech hopes to use antibodies and light to destroy cancer cells while leaving healthy tissues unharmed. 

Nearly three years after it first teamed up with Takeda, PRA Health Sciences has bought out its joint venture with the Japanese pharma.

Boston Biomedical is halting a late-stage study of its investigational drug, alongside older chemo therapies, after it failed to help pancreatic cancer patients.

Just days after Daiichi’s Xospata challenger scored approval in Japan for a form of acute myeloid leukemia, the FDA declined to clear the drug in the U.S.